Global law firm Hogan Lovells advised Villaris Therapeutics, a biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo, in a sale to global pharmaceutical company Incyte. Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize Villaris’ lead asset, monoclonal antibody auremolimab, for all uses, including for vitiligo and other autoimmune and inflammatory diseases. Further details can be found here.
Villaris’ shareholders will receive US$70 million in upfront payments and be eligible for up to US$310 million upon achievement of certain development and regulatory milestones, as well as up to an additional US$1.05 billion in commercial milestones on net sales of the product.
